Evidence map›Paper›PMID 26445283›Full record

Observational studyPloS one2015

Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

Iris Chen, William Clarke, San-San Ou, Mark A Marzinke, Autumn Breaud, Lynda M Emel, Jing Wang, James P Hughes, Paul Richardson, Danielle F Haley and 5 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Iris ChenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
San-San OuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Mark A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Autumn BreaudDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Lynda M EmelVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Jing WangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
James P HughesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Paul RichardsonDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Danielle F HaleyDepartment of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
Jonathan LucasScience Facilitation Department, FHI 360, Durham, North Carolina, United States of America.
Anne RompaloDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Jessica E JustmanICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, United States of America.
Sally L HodderClinical and Translational Science Institute, West Virginia University, Morgantown, West Virginia, United States of America.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Fred Hutch Cancer Center · USJohns Hopkins Medicine · USJohns Hopkins University · USColumbia University · USEmory University · USFamily Health International 360 · USWest Virginia University · US

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Neighborhood Factors, Sexual Risk, and STIs in HIV-Infected and High-Risk WomenF31MH105238 · NIMH · EMORY UNIVERSITY · PI HALEY, DANIELLE FRANCES · 2014 to 2015
$82k
NIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1-AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI069470NIGMS NIH HHS T32 GM008752NIGMS NIH HHS U54 GM104942NIMH NIH HHS F31 MH105238
6 · The paper itself

Abstract

Antiretroviral (ARV) drug use was analyzed in HIV-uninfected women in an observational cohort study conducted in 10 urban and periurban communities in the United States with high rates of poverty and HIV infection. Plasma samples collected in 2009-2010 were tested for the presence of 16 ARV drugs. ARV drugs were detected in samples from 39 (2%) of 1,806 participants: 27/181 (15%) in Baltimore, MD and 12/179 (7%) in Bronx, NY. The ARV drugs detected included different combinations of non-nucleoside reverse transcriptase inhibitors and protease inhibitors (1-4 drugs/sample). These data were analyzed in the context of self-reported data on ARV drug use. None of the 39 women who had ARV drugs detected reported ARV drug use at any study visit. Further research is needed to evaluate ARV drug use by HIV-uninfected individuals.

Indexed as

AdultAnti-Retroviral AgentsCohort StudiesFemaleHIVHIV InfectionsHumansMaleMiddle AgedRisk-TakingSexual BehaviorUnited StatesYoung AdultAnti-Retroviral Agents

Identifiers

PMID26445283
PMCPMC4596522
OpenAlexW2210986344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.